ARROWHEAD PHARMACEUTICALS, INC.

(A2AGYB)
  Bericht
Realtime-Estimate Cboe BZX  -  19/05 21:31:22
34.87 USD   +1.94%
13.05.ARROWHEAD PHARMACEUTICALS, INC. : B. Riley bekräftigt seine Kaufempfehlung
MM
11.05.ARROWHEAD PHARMACEUTICALS, INC. : Piper Sandler behält seine Kaufempfehlung bei
MM
11.05.ARROWHEAD PHARMACEUTICALS, INC. : Chardan Research bekräftigt seine Kaufempfehlung
MM
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über ARROWHEAD PHARMACEUTICALS, INC.
12.05.TRANSCRIPT : Arrowhead Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare C..
12.05.NORTH AMERICAN MORNING BRIEFING : Stocks Seen -3-
11.05.INFLATION : Have we passed the peak yet?
11.05.ANALYST RECOMMENDATIONS : Electronic Arts, Corning, Arrowhead Pharma, Tesla, Wynn Resorts...
10.05.TRANSCRIPT : Arrowhead Pharmaceuticals, Inc., Q2 2022 Earnings Call, May 10, 2022
10.05.ARROWHEAD PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
10.05.Arrowhead Pharmaceuticals Swings to Profit in Fiscal Q2 as Revenue Rises
10.05.Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
10.05.Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six..
10.05.EARNINGS REACTION HISTORY : Arrowhead Pharma Inc, 40.0% Follow-Through Indicator, 6.5% Sen..
09.05.Arrowhead Pharmaceuticals Starts Construction of Manufacturing Facility in Wisconsin
09.05.Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Ever..
09.05.Arrowhead Pharmaceuticals, Inc. Breaks Ground on New Manufacturing Facility
05.05.ARROWHEAD PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
02.05.Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors
02.05.Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences
02.05.Arrowhead Pharmaceuticals, Inc. Appoints Victoria Vakiener to Board of Directors
27.04.Arrowhead Pharmaceuticals to Host Pulmonary R&D Day
26.04.Arrowhead Pharmaceuticals Launches Phase 2 Study of ARO-ANG3 to Treat Homozygous Famili..
26.04.Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 f..
26.04.Arrowhead Pharmaceuticals Inc. Doses the First Patients in the Phase 2 GATEWAY Clinical..
25.04.ARROWHEAD PHARMACEUTICALS : Dia fda 2022 aro-hif2
25.04.Arrowhead Pharmaceuticals, Vivo Capital Form Joint Venture to Expand Reach of Innovativ..
25.04.ARROWHEAD PHARMACEUTICALS : and Vivo Capital Launch Joint Venture Aimed at Greater China M..
25.04.ARROWHEAD PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhib..
25.04.Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China ..
25.04.Arrowhead Pharmaceuticals and Vivo Capital Form Joint Venture, Visirna Therapeutics to ..
20.04.Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results
14.04.ARROWHEAD PHARMACEUTICALS : AACR 2022 ARO-HIF2 Poster
13.04.ARROWHEAD PHARMACEUTICALS : APASL 2022 JNJ-3989 in Healthy Chinese
13.04.ARROWHEAD PHARMACEUTICALS : APASL 2022 JNJ-3989 in Hepatic Impaired
13.04.ARROWHEAD PHARMACEUTICALS : Apasl 2022 jnj-3989
07.04.Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
06.04.Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4..
04.04.Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
01.04.Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
24.03.SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Thursday
24.03.Arrowhead Pharmaceuticals Files for Regulatory Clearance to Study Potential Treatment f..
24.03.Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for..
24.03.Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a S..
18.03.ARROWHEAD PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (for..
15.03.Arrowhead Pharmaceuticals Seeks Regulatory Approval for Trial of Investigational Asthma..
15.03.Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for T..
15.03.Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a S..
07.03.GLASS LEWIS ESG CONTROVERSY ALERT : Arrowhead Pharmaceuticals
01.03.SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arrow..
24.02.Arrowhead Pharmaceuticals Says Patient Enrollment is Complete in Study of Mixed Dyslipi..
24.02.Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 f..
24.02.Arrowhead Pharmaceuticals Inc. Completes Enrollment in Phase 2b ARCHES-2 Study of Inves..
21.02.SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arrow..
18.02.Arrowhead Pharmaceuticals Begins 1/2 Study of Drug to Treat Complement Mediated Disease..
18.02.Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Compleme..
18.02.Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2 Study of ARO-C3 for Treatment of Co..
17.02.ARROWHEAD PHARMACEUTICALS : Initial results from the phase 1 study of ARO-HIF2 to silence ..
17.02.Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022
17.02.Arrowhead Pharmaceuticals, Inc. Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022
14.02.INSIDER SELL : Arrowhead Pharmaceuticals
02.02.TRANSCRIPT : Arrowhead Pharmaceuticals, Inc., Q1 2022 Earnings Call, Feb 02, 2022
02.02.ARROWHEAD PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
02.02.Arrowhead Pharmaceuticals Fiscal Q1 Net Loss Widens, Revenue Rises
02.02.Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended De..
02.02.ARROWHEAD PHARMACEUTICALS : Reports Fiscal 2022 First Quarter Results - Form 8-K
02.02.Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
02.02.Earnings Flash (ARWR) ARROWHEAD PHARMACEUTICALS Reports Q1 Loss $-0.60
02.02.Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended Fe..
02.02.EARNINGS REACTION HISTORY : Arrowhead Pharma Inc, 57.1% Follow-Through Indicator, 7.4% Sen..
24.01.Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
24.01.Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline
24.01.Arrowhead Pharmaceuticals Announces Closing of Agreement with Glaxosmithkline
21.01.Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
12.01.Arrowhead Pharmaceuticals Commences Dosing in Phase 3 Trial of Treatment for Familial C..
12.01.Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment o..
12.01.Arrowhead Pharmaceuticals Inc Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatme..
10.01.INSIDER SELL : Arrowhead Pharmaceuticals
07.01.INSIDER SELL : Arrowhead Pharmaceuticals
1  2  3  4  5  6  7  8  9Weiter
Anstehende Termine für ARROWHEAD PHARMACEUTICALS, INC.